| Primary information |
|---|
| ID | 11409 |
| Uniprot ID | P14200 |
| Description | Pro-MCH precursor [Cleaved into- - Neuropeptide-glycine-glutamic acid (NGE)(Neuropeptide G-E); Neuropeptide-glutamic acid-isoleucine (NEI)(Neuropeptide E-I); Melanin-concentrating hormone (MCH)]. |
| Organism | Rattus norvegicus |
| Txonomy | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;Muroidea; Muridae; Murinae; Rattus. |
| Subcellular Location | Secreted |
| Developmental Stage | Expression is strongly increased in hypothalamus between postnatal days 12 and 20; to reach high constant values in adult. |
| Similarity | Belongs to the melanin-concentrating hormone family. |
| Tissue Specificity | MCH is present in all regions of the brain and in neurointermediate lobe of the pituarity gland; with highest concentrations in the hypothalamus. Also expressed to a much lesser extent in stomach; lam |
| Post Translational Modification | Pro-MCH is processed differentially in the brain and in peripheral organs producing two neuropeptides; NEI and MCH. A third peptide; NGE; may also be produced. Preferential processing in neurons by pr |
| Function | NEI can influence differentiation of neuronal processes in brain neurons. Affects the content of neurofilament protein in neuritogenesis (in vitro). May also be a neuromodulatory factor. In behavioral tests; it stimulates exploration and anxiety when injected into the ventromedial nucleus. Also stimulates grooming; locomotion and rearing. May antagonize the inhibitory effect of mch on ACTH release. Reduces dopamine and dopac release in the ventromedial nucleus |
| Length | 165 |
| Molecular Weight | 18482 |
| Name | Neuropeptide-glutamic acid-isoleucine |
| Sequence | EIGDEENSAKFPI |
| Sequence map | 13 (131-143) |
| PDB ID | NA |
| Drugpedia | NA |
| Receptor | P97639 |
| Domain | NA |
| Pharmaceutical Use | NA
|